PI(3) kinase is associated with a mechanism of immunoresistance in breast and prostate cancer

Oncogene

Volumn 28, Issue 2, 2009, Pages 306-312

  Crane, C A ^a   Panner, A ^a   Murray, J C ^a   Wilson, S P ^a   Xu, H ^b   Chen, L ^b   Simko, J P ^c   Waldman, F M ^a   Pieper, R O ^a   Parsa, A T ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

B7 H1; Breast cancer; Immunoresistance; PI(3) kinase; Prostate cancer; T cell

Indexed keywords

DNA; MESSENGER RNA; MUTANT PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; BREAST CARCINOMA; CONTROLLED STUDY; ENZYME ACTIVATION; FLOW CYTOMETRY; GENE EXPRESSION; GENE MUTATION; GENE TARGETING; HUMAN; HUMAN CELL; LYMPHOCYTE FUNCTION; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN EXPRESSION; T LYMPHOCYTE; TUMOR IMMUNITY;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADENOCARCINOMA; ANTIGENS, CD; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; MALE; NEOPLASM PROTEINS; PHENOTYPE; PROSTATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; PTEN PHOSPHOHYDROLASE; RECOMBINANT FUSION PROTEINS; RIBOSOMAL PROTEIN S6 KINASES; RNA, SMALL INTERFERING; T-LYMPHOCYTES, CYTOTOXIC; TUMOR ESCAPE;

EID: 58249112908     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2008.384     Document Type: Article

References (37)

1. Baleeiro RB, Barbuto JA. (2008). Local secretion/shedding of tumor-derived CD83 molecules as a novel tumor escape mechanism. Mol Immunol 45: 3502-3504.
2. Bui JD, Schreiber RD. (2007). Cancer immunosurveillance, immunoediting and inflammation: independent or interdependent processes? Curr Opin Immunol 19: 203-208.
3. Chang YC, Chen TC, Lee CT, Yang CY, Wang HW, Wang CC et al. (2008). Epigenetic control of MHC-II expression in tumor-associated macrophages by decoy receptor 3. Blood 111: 5054-5063.
4. Dey N, Crosswell HE, De P, Parsons R, Peng Q, Su JD et al. (2008). The protein phosphatase activity of PTEN regulates SRC family kinases and controls glioma migration. Cancer Res 68: 1862-1871.
5. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB et al. (2002). Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 8: 793-800.
6. Geng L, Huang D, Liu J, Qian Y, Deng J, Li D et al. (2008). B7-H1 up-regulated expression in human pancreatic carcinoma tissue associates with tumor progression. J Cancer Res Clin Oncol 134: 1021-1027.
7. Gingras AC, Kennedy SG, O'Leary MA, Sonenberg N, Hay N. (1998). 4E-BP1, a repressor of mRNA translation, is phosphorylated and inactivated by the Akt(PKB) signaling pathway. Genes Dev 12: 502-513.
8. Inman BA, Sebo TJ, Frigola X, Dong H, Bergstralh EJ, Frank I et al. (2007). PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression. Cancer 109: 1499-1505.
9. Johnson LE, Frye TP, Chinnasamy N, Chinnasamy D, McNeel DG. (2007). Plasmid DNA vaccine encoding prostatic acid phosphatase is effective in eliciting autologous antigen-specific CD8+ T cells. Cancer Immunol Immunother 56: 885-895.
10. Koebel CM, Vermi W, Swann JB, Zerafa N, Rodig SJ, Old LJ et al. (2007). Adaptive immunity maintains occult cancer in an equilibrium state. Nature 450: 903-907.
11. Kozikowski AP, Sun H, Brognard J, Dennis PA. (2003). Novel PI analogues selectively block activation of the pro-survival serine/threonine kinase Akt. J Am Chem Soc 125: 1144-1145.
12. Krambeck AE, Dong H, Thompson RH, Kuntz SM, Lohse CM, Leibovich BC et al. (2007). Survivin and b7-h1 are collaborative predictors of survival and represent potential therapeutic targets for patients with renal cell carcinoma. Clin Cancer Res 13: 1749-1756.
13. Liu VC, Wong LY, Jang T, Shah AH, Park I, Yang X et al. (2007). Tumor evasion of the immune system by converting CD4+CD25-T cells into CD4+CD25+ T regulatory cells: role of tumor-derived TGF-beta. J Immunol 178: 2883-2892.
14. Loos M, Giese NA, Kleeff J, Giese T, Gaida MM, Bergmann F et al. (2008). Clinical significance and regulation of the costimulatory molecule B7-H1 in pancreatic cancer. Cancer Lett 268: 98-109.
15. Martin KA, Blenis J. (2002). Coordinate regulation of translation by the PI 3-kinase and mTOR pathways. Adv Cancer Res 86: 1-39.
16. Mazanet MM, Hughes CC. (2002). B7-H1 is expressed by human endothelial cells and suppresses T cell cytokine synthesis. J Immunol 169: 3581-3588.
17. Meyer RG, Korn S, Micke P, Becker K, Huber C, Wolfel T et al. (2007). An open-label, prospective phase I/II study evaluating the immunogenicity and safety of a ras peptide vaccine plus GM-CSF in patients with non-small cell lung cancer. Lung Cancer 58: 88-94.
18. Miled N, Yan Y, Hon WC, Perisic O, Zvelebil M, Inbar Y et al. (2007). Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit. Science 317: 239-242.
19. Mittendorf EA, Peoples GE, Singletary SE. (2007). Breast cancer vaccines: promise for the future or pipe dream? Cancer 110: 1677-1686.
20. Parsa AT, Waldron JS, Panner A, Crane CA, Parney IF, Barry JJ et al. (2007). Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med 13: 84-88.
21. Penn I. (1996). Malignant melanoma in organ allograft recipients. Transplantation 61: 274-278.
22. Powell Jr DJ, Dudley ME, Hogan KA, Wunderlich JR, Rosenberg SA. (2006). Adoptive transfer of vaccine-induced peripheral blood mononuclear cells to patients with metastatic melanoma following lymphodepletion. J Immunol 177: 6527-6539.
23. Roth TJ, Sheinin Y, Lohse CM, Kuntz SM, Frigola X, Inman BA et al. (2007). B7-H3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy. Cancer Res 67: 7893-7900.
24. Routh JC, Ashley RA, Sebo TJ, Lohse CM, Husmann DA, Kramer SA et al. (2008). B7-H1 expression in Wilms tumor: correlation with tumor biology and disease recurrence. J Urol 179: 1954-1959; discussion 1959-1960.
25. Schartner JM, Hagar AR, Van Handel M, Zhang L, Nadkarni N, Badie B. (2005). Impaired capacity for upregulation of MHC class II in tumor-associated microglia. Glia 51: 279-285.
26. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ et al. (2001). IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410: 1107-1111.
27. Siva A, Xin H, Qin F, Oltean D, Bowdish KS, Kretz-Rommel A. (2008). Immune modulation by melanoma and ovarian tumor cells through expression of the immunosuppressive molecule CD200. Cancer Immunol Immunother 57: 987-996.
28. Slingluff Jr CL, Petroni GR, Chianese-Bullock KA, Smolkin ME, Hibbitts S, Murphy C et al. (2007). Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting. Clin Cancer Res 13: 6386-6395.
29. Slovin SF. (2008). Pitfalls or promise in prostate cancer immunotherapy-which is winning? Cancer J 14: 26-34.
30. Small EJ, Tchekmedyian NS, Rini BI, Fong L, Lowy I, Allison JP. (2007). A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin Cancer Res 13: 1810-1815.
31. Tamura M, Gu J, Matsumoto K, Aota S, Parsons R, Yamada KM. (1998). Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN. Science 280: 1614-1617.
32. Thompson RH, Dong H, Kwon ED. (2007). Implications of B7-H1 expression in clear cell carcinoma of the kidney for prognostication and therapy. Clin Cancer Res 13: 709s-715s.
33. Thompson RH, Gillett MD, Cheville JC, Lohse CM, Dong H, Webster WS et al. (2004). Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci USA 101: 17174-17179.
34. Thompson RH, Kuntz SM, Leibovich BC, Dong H, Lohse CM, Webster WS et al. (2006). Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res 66: 3381-3385.
35. Wang L, Pino-Lagos K, de Vries VC, Guleria I, Sayegh MH, Noelle RJ. (2008). Programmed death 1 ligand signaling regulates the generation of adaptive Foxp3+CD4+ regulatory T cells. Proc Natl Acad Sci USA 105: 9331-9336.
36. Wintterle S, Schreiner B, Mitsdoerffer M, Schneider D, Chen L, Meyermann R et al. (2003). Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis. Cancer Res 63: 7462-7467.
37. Zang X, Thompson RH, Al-Ahmadie HA, Serio AM, Reuter VE, Eastham JA et al. (2007). B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proc Natl Acad Sci USA 104: 19458-19463.